Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety

Abstract

Despite achieving optimal LDL-C levels with statin therapy, the risk of cardiovascular events persists in the majority of dyslipidemic patients. In particular, patients with mixed dyslipidemia, who have continued elevation of triglycerides and decreased HDL-C, have substantial residual cardiovascular risk. Thus, patients with multiple abnormal lipid parameters may require combination lipid drug therapy. Current guidelines recommend more intensive goals for LDL-C in high-risk patients, as well as combination treatment with agents that target triglycerides and HDL-C in these patients with mixed dyslipidemia. Clinical trials of rosuvastatin plus fenofibric acid suggest that this is an efficacious and safe strategy for the treatment of mixed dyslipidemia.

Keywords:

• combination therapy
• fenofibric acid
• HDL-C
• LDL-C
• mixed dyslipidemia
• rosuvastatin
• triglyceride